Rani Therapeutics Statistics
Share Statistics
Rani Therapeutics has 57.54M
shares outstanding. The number of shares has increased by 13.62%
in one year.
| Shares Outstanding | 57.54M |
| Shares Change (YoY) | 13.62% |
| Shares Change (QoQ) | -0.24% |
| Owned by Institutions (%) | 13.24% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 12,694 |
| FTD / Avg. Volume | 3.23% |
Short Selling Information
The latest short interest is 2.35M, so 6.99% of the outstanding
shares have been sold short.
| Short Interest | 2.35M |
| Short % of Shares Out | 6.99% |
| Short % of Float | 9.87% |
| Short Ratio (days to cover) | 14.33 |
Valuation Ratios
The PE ratio is -1.3 and the forward
PE ratio is -0.83.
Rani Therapeutics's PEG ratio is
0.06.
| PE Ratio | -1.3 |
| Forward PE | -0.83 |
| PS Ratio | 37.95 |
| Forward PS | 0.5 |
| PB Ratio | 19.58 |
| P/FCF Ratio | -1.09 |
| PEG Ratio | 0.06 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Rani Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.5,
with a Debt / Equity ratio of 14.91.
| Current Ratio | 1.5 |
| Quick Ratio | 1.5 |
| Debt / Equity | 14.91 |
| Debt / EBITDA | -0.59 |
| Debt / FCF | -0.83 |
| Interest Coverage | -10.59 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $9,790.48 |
| Profits Per Employee | $-285,885.71 |
| Employee Count | 105 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 26.57M |
| Effective Tax Rate | -88.5% |
Stock Price Statistics
The stock price has increased by -86.04% in the
last 52 weeks. The beta is 0.25, so Rani Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.25 |
| 52-Week Price Change | -86.04% |
| 50-Day Moving Average | 1.1 |
| 200-Day Moving Average | 1.8 |
| Relative Strength Index (RSI) | 33.52 |
| Average Volume (20 Days) | 392,834 |
Income Statement
In the last 12 months, Rani Therapeutics had revenue of 1.03M
and earned -30.02M
in profits. Earnings per share was -1.05.
| Revenue | 1.03M |
| Gross Profit | 1.03M |
| Operating Income | -53.31M |
| Net Income | -30.02M |
| EBITDA | -50.52M |
| EBIT | -51.55M |
| Earnings Per Share (EPS) | -1.05 |
Full Income StatementBalance Sheet
The company has 3.76M in cash and 29.71M in
debt, giving a net cash position of -25.95M.
| Cash & Cash Equivalents | 3.76M |
| Total Debt | 29.71M |
| Net Cash | -25.95M |
| Retained Earnings | -102.91M |
| Total Assets | 24.13M |
| Working Capital | -2.35M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -35.5M
and capital expenditures -268K, giving a free cash flow of -35.76M.
| Operating Cash Flow | -35.5M |
| Capital Expenditures | -268K |
| Free Cash Flow | -35.76M |
| FCF Per Share | -1.26 |
Full Cash Flow StatementMargins
Gross margin is 100%, with operating and profit margins of -5186.19% and -2920.04%.
| Gross Margin | 100% |
| Operating Margin | -5186.19% |
| Pretax Margin | -2920.04% |
| Profit Margin | -2920.04% |
| EBITDA Margin | -4914.69% |
| EBIT Margin | -5186.19% |
| FCF Margin | -3478.99% |
